• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

    11/10/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ROIV alert in real time by email

    BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total.

    "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continues to be a privilege to work alongside him every day," said Matt Gline, CEO of Roivant.

    Mayukh Sukhatme, M.D., has served as Roivant's President and Chief Investment Officer since January 2021, and is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for the company. Dr. Sukhatme also informs Roivant's view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as our Chief Business Officer. Programs that Dr. Sukhatme has in-licensed or acquired for Roivant have produced all 10 of our positive Phase 3 studies and have garnered 6 FDA approvals. From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.

    About Roivant

    Roivant is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Today, Roivant's pipeline includes VTAMA®, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor ("FcRn") in development across several IgG-mediated autoimmune indications; brepocitinib, a novel TYK2/JAK1 inhibitor in late stage development for dermatomyositis, systemic lupus erythematosus, and other autoimmune conditions; and, additional clinical stage molecules. We advance our pipeline by creating nimble subsidiaries or "Vants" to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.

    Roivant Forward-Looking Statements

    This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

    Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the pending sale of our subsidiary Telavant to Roche (the "Telavant Transaction"), the clinical and therapeutic potential of our products and product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our products and product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

    Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contacts:

    Investors

    Roivant Investor Relations

    [email protected]

    Media

    Stephanie Lee

    Roivant Sciences

    [email protected]



    Primary Logo

    Get the next $ROIV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ROIV

    DatePrice TargetRatingAnalyst
    2/15/2024$17.00Outperform
    Wolfe Research
    1/5/2024$20.00Overweight
    Piper Sandler
    12/12/2023$14.00Buy
    Deutsche Bank
    10/17/2023$17.00Buy
    Guggenheim
    6/8/2023$10.50Neutral
    BofA Securities
    10/27/2022$7.00Overweight
    JP Morgan
    5/23/2022$6.00Outperform
    SVB Leerink
    4/29/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ROIV
    Financials

    Live finance-specific insights

    See more
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ROIV
    Leadership Updates

    Live Leadership Updates

    See more
    • Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

      NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

      3/26/24 6:22:00 PM ET
      $PGTI
      $ROIV
      $RUN
      $SPGI
      Building Products
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

      BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

      11/10/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

        BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T

      10/13/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Roivant Sciences with a new price target

      Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00

      2/15/24 6:44:53 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Roivant Sciences with a new price target

      Piper Sandler initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $20.00

      1/5/24 8:43:06 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Roivant Sciences with a new price target

      Deutsche Bank initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $14.00

      12/12/23 8:08:23 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ramaswamy Vivek sold $10,129,810 worth of shares (898,959 units at $11.27), decreasing direct ownership by 2% to 39,174,611 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/8/25 8:51:50 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Pulik Richard covered exercise/tax liability with 1,653 shares, decreasing direct ownership by 0.41% to 405,699 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      4/30/25 9:00:14 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Pulik Richard was granted 141,464 shares, increasing direct ownership by 53% to 407,352 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      4/23/25 9:00:21 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    SEC Filings

    See more
    • SEC Form 144 filed by Roivant Sciences Ltd.

      144 - Roivant Sciences Ltd. (0001635088) (Subject)

      5/7/25 4:37:34 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Roivant Sciences Ltd.

      144 - Roivant Sciences Ltd. (0001635088) (Subject)

      5/6/25 4:21:17 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Roivant Sciences Ltd. (0001635088) (Filer)

      4/21/25 7:42:40 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/14/24 4:31:06 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 4:58:58 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Roivant Sciences Ltd.

      SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 10:34:18 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care